🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#NEWS: The FDA granted Orphan Drug Designation to our antibody-drug conjugate candidate for the treatment of small cell lung cancer. This is an important step for Zai’s global oncology pipeline, with a potential highly active first-in-class DLL3 #ADC. bit.ly/3PNuXHa

Happy Lunar New Year! We’re celebrating the arrival of spring and the beginning of a new year on the lunar calendar. Zai Lab wishes you good luck and prosperity as we enter the Year of the Snake. #ChineseNewYear #LunarNewYear

This year’s #WorldCancerDay theme, #UnitedByUnique, is a reminder to advocate for people-centered care. Zai Lab is committed to a patient-first approach to health care, including cancer treatment. Learn how we can unite to support those affected by cancer: bit.ly/4hIDPd2

In a recent announcement, our founder and CEO Dr. Samantha Du highlighted Zai Lab’s strong momentum. Learn more about our pipeline progress and healthcare #innovation: bit.ly/41llQmi #biotechnology $ZLab #ADC #healthcare

Dr. Samantha Du, our CEO and founder recently highlighted key updates, such as progress with Zai Lab’s global asset, ZL-1310, reinforcing its potential as a first- and best-in-class DLL3 antibody-drug conjugate for the treatment of small cell lung cancer. bit.ly/41llQmi

Dr. Rafael Amado joined the Empowered Patient Podcast with EmpoweredPatient to discuss the “renaissance” of advancements in antibody-drug conjugate research. Listen to the full podcast: bit.ly/4hRCxvT #innovation #healthcare #ADC

#NEWS: Zai Lab at #AACR25! Presentations will highlight data from preclinical studies of both ZL-6201, an LRRC15 antibody-drug conjugate for the treatment of sarcoma, and ZL-1222, an IL-12 immunocytokine for cancer immunotherapy. bit.ly/4l9xSYZ #ADC #AACR25 #oncology

On #WorldHealthDay, we join World Health Organization (WHO) in supporting a campaign focused on maternal and newborn health. At Zai Lab, we believe investing in women’s health sustains lifelong wellbeing, stronger communities, and a brighter future for everyone. bit.ly/4iDiwKA #HopefulFutures

In an interview with BioSpectrum Asia, Dr. Rafael Amado, Zai Lab’s Head of Global R&D, discussed the resurgence of antibody-drug conjugates in cancer therapy & highlighted Zai Lab’s promising next-generation #ADC pipeline. Read more: bit.ly/3GmhUL6 #oncology #research

#NEWS: Zai Lab will present data at #ASCO25. We're excited to highlight the potential of ZL-1310 as a promising first-in-class and best-in-class DLL3-targeted #ADC for patients with extensive-stage small cell lung cancer. Learn more: bit.ly/44AkYNN #oncology #ADC

#NEWS: Zai Lab is proud to present data on our next-gen oncology therapies at #AACR25. Studies include ZL-6201, an LRRC15 #ADC targeting multiple solid tumors, and ZL-1222, an anti-PD-1/IL-12 immunocytokine for cancer immunotherapy Learn more: bit.ly/3YEOLBt #oncology

Our Executive Director of Biology, Dr. Bing Wan, and our Senior VP of Biologics Discovery, Dr. Linda Liu, presented new data on ZL-6201 and ZL-1222, two next-generation investigational oncology therapies, at #AACR25. bit.ly/3YEOLBt #oncology #ADC #healthcare #biotech

#NEWS: Dr. Rafael Amado recently spoke with Scrip’s Dexter Jie Yan about Zai Lab’s commitment to advancing next-generation oncology therapies with global rights. Read the full interview to learn more about our progress and vision: bit.ly/3YquXSd #ADC #oncology

#NEWS: Today Zai Lab announced financial results for the first quarter of 2025. Learn more about our pipeline progress and healthcare #innovation: bit.ly/4drRxQJ #earnings #financialresults #oncology #ADC #healthcare

Zai received U.S. FDA Fast Track Designation for ZL-1310, a first-in-class DLL-3-targeted antibody-drug conjugate (ADC), for treatment of extensive-stage small cell lung cancer. We will present updated results from our Phase 1 trial of ZL-1310 at #ASCO25. bit.ly/3SQ5uOx

On International Day of Action for Women’s Health, we are committed to advancing women's health through innovative treatments that have the potential to make a significant impact in the fight against cervical and ovarian cancers. Learn more: bit.ly/4kftJBS #womenshealth

#NEWS: Zai Lab presents positive Phase 1 data for ZL-1310, our potential first-in-class, Delta-like ligand-targeted (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC) at #ASCO2025. Read more: bit.ly/3SyFlUC #ADC

Zai Lab to present new preclinical data for ZL-1503, an IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis, at #EEACI25 in Glasgow, Scotland. Read more: bit.ly/45mvwAI

In a Pharmaceutical Executive article, our Global Head of R&D discusses the renaissance in antibody-drug conjugate (ADC) development. Learn how novel #ADC technology has the potential to expand access to #cancer treatment with innovative approaches & improved outcomes: bit.ly/405EtL8

#NEWS: Zai Lab announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. bit.ly/3TlLdkl #healthcare #innovation #oncology